Brooklyn Piotroski F Score

BTX
 Stock
  

USD 0.57  0.03  5.00%   

This module uses fundamental data of Brooklyn Immunotherapeuti to approximate its Piotroski F score. Brooklyn Immunotherapeuti F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Brooklyn Immunotherapeutics. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Brooklyn Immunotherapeuti financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Continue to Brooklyn Immunotherapeuti Altman Z Score, Brooklyn Immunotherapeuti Correlation, Brooklyn Immunotherapeuti Valuation, as well as analyze Brooklyn Immunotherapeuti Alpha and Beta and Brooklyn Immunotherapeuti Hype Analysis.
  
Refresh
Brooklyn Immunotherapeuti Total Debt is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Total Debt of 2.72 Million in 2021. Debt Current is likely to rise to about 437.2 K in 2022, whereas Issuance Repayment of Debt Securities is likely to drop (966.8 K) in 2022. Brooklyn Immunotherapeuti Current Ratio is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Current Ratio of 5.10 in 2021. Debt to Equity Ratio is likely to rise to 4.30 in 2022, whereas Return on Investment is likely to drop (24.25)  in 2022.
At this time, it appears that Brooklyn Immunotherapeuti's Piotroski F Score is Poor. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
4.0
Piotroski F Score - Poor
1
Current Return On AssetsNegativeFocus
2
Change in Return on AssetsDecreasedFocus
3
Cash Flow Return on AssetsNegativeFocus
4
Current Quality of Earnings (accrual)ImprovingFocus
5
Asset Turnover GrowthIncreaseFocus
6
Current Ratio ChangeIncreaseFocus
7
Long Term Debt Over Assets ChangeHigher LeverageFocus
8
Change In Outstending SharesIncreaseFocus
9
Change in Gross MarginIncreaseFocus

Brooklyn Immunotherapeuti Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Brooklyn Immunotherapeuti is to make sure Brooklyn is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Brooklyn Immunotherapeuti's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Brooklyn Immunotherapeuti's financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares46.7 M43.3 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted46.7 M43.3 M
Significantly Up
Increasing
Slightly volatile
Net Cash Flow from Operations(24.1 M)(23.5 M)
Fairly Down
Decreasing
Slightly volatile
Total Assets26.9 M32.4 M
Significantly Down
Increasing
Slightly volatile
Total Liabilities20.6 M25.9 M
Significantly Down
Increasing
Slightly volatile
Current Assets20.2 M18.8 M
Significantly Up
Increasing
Slightly volatile
Current LiabilitiesM3.7 M
Significantly Up
Increasing
Very volatile
Total Debt3.8 M2.7 M
Significantly Up
Increasing
Slightly volatile
Gross Margin0.570.56
Fairly Up
Decreasing
Slightly volatile
Asset Turnover1.261.17
Significantly Up
Decreasing
Slightly volatile

Brooklyn Immunotherapeuti F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Brooklyn Immunotherapeuti's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Brooklyn Immunotherapeuti in a much-optimized way.

About Brooklyn Immunotherapeuti Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Weighted Average Shares

46.72 Million

Share
Brooklyn Immunotherapeuti Weighted Average Shares is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Weighted Average Shares of 43.31 Million in 2021

Brooklyn Immunotherapeuti Current Valuation Drivers

We derive many important indicators used in calculating different scores of Brooklyn Immunotherapeuti from analyzing Brooklyn Immunotherapeuti's financial statements. These drivers represent accounts that assess Brooklyn Immunotherapeuti's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Brooklyn Immunotherapeuti's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(210.27 K)(582.15 K)(212.89 K)(374.41 K)(430.57 K)(464.56 K)
Revenue Per Employee36.4 K63.14 K63.91 K33.11 K38.08 K52.38 K
Average Assets17.55 M15.62 M15.29 M9.16 M39.31 M42.41 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA1.8 M2.83 M1.4 M(26.43 M)(121.84 M)(125.05 M)
Earnings Before Interest Taxes and Depreciation Amortization USD1.8 M2.83 M1.4 M(26.43 M)(121.84 M)(125.05 M)
Earnings before Tax(1.01 M)(323 K)(2.02 M)(26.53 M)(122.3 M)(125.52 M)
Average Equity5.86 M6.39 M6.2 M(1.33 M)12.58 M13.57 M
Enterprise Value11.7 M6.81 M10.23 M8.31 M195.87 M211.33 M
Free Cash Flow(903 K)(214 K)1.65 M(8.14 M)(23.64 M)(24.26 M)
Invested Capital5.39 M9.38 M8.24 M9.88 M12.45 M11.36 M
Invested Capital Average5.34 M8.47 M11.74 M5.76 M10.43 M9.75 M
Market Capitalization10.61 M5.6 M6.38 M6.64 M217.02 M234.16 M
Tangible Asset Value14.11 M12.18 M11.51 M11.73 M30.39 M24.28 M
Working Capital(1.11 M)2.76 M(25 K)(1.39 M)15.09 M16.28 M

About Brooklyn Immunotherapeuti Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Brooklyn Immunotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brooklyn Immunotherapeuti using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brooklyn Immunotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. Brooklyn Immunotherapeuti operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 10 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Brooklyn Immunotherapeuti without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Fundamental Analysis Now

   

Fundamental Analysis

View fundamental data based on most recent published financial statements
All  Next Launch Module
Continue to Brooklyn Immunotherapeuti Altman Z Score, Brooklyn Immunotherapeuti Correlation, Brooklyn Immunotherapeuti Valuation, as well as analyze Brooklyn Immunotherapeuti Alpha and Beta and Brooklyn Immunotherapeuti Hype Analysis. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
33 M
Return On Assets
-0.74
Return On Equity
-156.16
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.